NCT06536400 - Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation | Biotech Hunter

Enrollment

316

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

August 30, 2026

Study Completion Date

July 7, 2027

Conditions

Solid Tumors

Interventions

DRUG

HSK42360

Oral administration, QD

Trial Locations (13)

100034

RECRUITING

Peking University First Hospital, Beijing

100070

RECRUITING

Beijing TianTan Hospital,Capital Medical University, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

201321

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

210000

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

310006

RECRUITING

Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou

350005

RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

410000

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Hunan Cancer Hospital, Changsha

450099

RECRUITING

The Third People's Hospital of Zhengzhou, Zhengzhou

510145

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

530012

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY